FDA Offers Orexigen Express Route to Contrave Resubmission

If just 6 percent of diabetes patients who are obese take Orexigen Therapeutics Inc.'s Contrave (naltrexone SR/bupropion SR), the company will reach $1 billion in sales in short order – assuming the FDA grants approval.